Development of Multi-omics integrated patient-derived 3D-Brain Metastases organoid platform to understand evolutionary pathways of brain colonization from the primary Triple negative Breast cancer (TNBC) tumor and to identify clinically actionable targets for precision nano-biotherapeutics strategies innovation
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- This study involves the development of patient-derived organoid models from clinical samples of individuals diagnosed with a specific subtype of breast cancer. The objective is to establish and characterize three-dimensional organoid systems derived from metastatic brain sites from primary breast tumor. The organoid platform will be leveraged to explore therapeutic sensitivities, with the broader goal of informing strategies for metastasis tumor growth from primary site.
研究概览
简要总结
This study aims to develop advanced laboratory models that replicate the progression of an aggressive form of breast cancer when it spreads to the brain. Such brain metastases are particularly difficult to diagnose and treat effectively, contributing to poor patient outcomes. By creating models derived from patient metastatic brain tumor samples, this research seeks to better understand how these cancers evolve and respond to treatment. The insights gained from this work may help identify why current therapies often fail and whether new treatment strategies can improve patient outcomes. Ultimately, the study hopes to contribute to the development of more effective interventions that could improve the survival and quality of life for patients facing this challenging disease.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 70.00 Year(s)（—）
- 性别
- Female
入选标准
- •Triple Negative Breast Cancer Patients with brain metastasis.
排除标准
- •Patients not willing to sign the informed consent form (Prospective part of study).
结局指标
主要结局
This study involves the development of patient-derived organoid models from clinical samples of individuals diagnosed with a specific subtype of breast cancer. The objective is to establish and characterize three-dimensional organoid systems derived from metastatic brain sites from primary breast tumor. The organoid platform will be leveraged to explore therapeutic sensitivities, with the broader goal of informing strategies for metastasis tumor growth from primary site.
时间窗: 24 months after surgery
次要结局
- Secondary aims of this study include the evaluation of organoid responses to conventional therapeutic agents, with the goal of identifying treatment patterns that may correlate with clinical outcomes. The organoid system will further serve as a platform to evaluate the feasibility of targeted delivery strategies across the blood-brain barrier.(36 months after surgery)